Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CKBA Ointment in Non-Segmental Vitiligo
ChiCTR2500108727Phase 2Completed
- Sponsor
- Hangzhou Third People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 3-O-cyclohexanecarbonyl-11-keto-beta-boswellic acid in Vitiligo (4 arms), sponsored by Hangzhou Third People's Hospital. Primary endpoint: Facial Vitiligo Area and Severity Index (F-VASI) at week 24. Started Sep 2025; status: completed.
02
Drugs
3-O-cyclohexanecarbonyl-11-keto-beta-boswellic acid
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2500108727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108727.